News >

Ixazomib Improves PFS as Frontline Maintenance in Multiple Myeloma

Gina Columbus
Published: Thursday, Nov 07, 2019

Phil Rowlands, PhD

Phil Rowlands, PhD

Ixazomib (Ninlaro) significantly improved progression-free survival (PFS) as a first-line maintenance therapy compared with placebo in adult patients with multiple myeloma who have not undergone stem cell transplantation, meeting the primary endpoint of the phase III TOURMALINE-MM4 study.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication